216 related articles for article (PubMed ID: 31050342)
1. PAX8 regulon in human ovarian cancer links lineage dependency with epigenetic vulnerability to HDAC inhibitors.
Shi K; Yin X; Cai MC; Yan Y; Jia C; Ma P; Zhang S; Zhang Z; Gu Z; Zhang M; Di W; Zhuang G
Elife; 2019 May; 8():. PubMed ID: 31050342
[TBL] [Abstract][Full Text] [Related]
2. SOX17 and PAX8 constitute an actionable lineage-survival transcriptional complex in ovarian cancer.
Lin L; Shi K; Zhou S; Cai MC; Zhang C; Sun Y; Zang J; Cheng L; Ye K; Ma P; Shen P; Zhang M; Cheng Y; Qi C; Li Y; Yin X; Zheng Y; Tan L; Zhuang G; Zang R
Oncogene; 2022 Mar; 41(12):1767-1779. PubMed ID: 35124696
[TBL] [Abstract][Full Text] [Related]
3. Histone Deacetylase Inhibitors Synergize with Catalytic Inhibitors of EZH2 to Exhibit Antitumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic Type.
Wang Y; Chen SY; Colborne S; Lambert G; Shin CY; Santos ND; Orlando KA; Lang JD; Hendricks WPD; Bally MB; Karnezis AN; Hass R; Underhill TM; Morin GB; Trent JM; Weissman BE; Huntsman DG
Mol Cancer Ther; 2018 Dec; 17(12):2767-2779. PubMed ID: 30232145
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and characterization of α, β-unsaturated carboxylic acid, and its urea based derivatives that explores novel epigenetic modulators in human non-small cell lung cancer A549 cell line.
Chidambaram A; Sundararaju K; Chidambaram RK; Subbiah R; Jayaraj JM; Muthusamy K; Vilwanathan R
J Cell Physiol; 2018 Jul; 233(7):5293-5309. PubMed ID: 29215703
[TBL] [Abstract][Full Text] [Related]
5. Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy.
Khabele D; Son DS; Parl AK; Goldberg GL; Augenlicht LH; Mariadason JM; Rice VM
Cancer Biol Ther; 2007 May; 6(5):795-801. PubMed ID: 17387270
[TBL] [Abstract][Full Text] [Related]
6. The effect of sodium butyrate and cisplatin on expression of EMT markers.
Mrkvicova A; Chmelarova M; Peterova E; Havelek R; Baranova I; Kazimirova P; Rudolf E; Rezacova M
PLoS One; 2019; 14(1):e0210889. PubMed ID: 30653577
[TBL] [Abstract][Full Text] [Related]
7. HDAC Inhibitor Oxamflatin Induces Morphological Changes and has Strong Cytostatic Effects in Ovarian Cancer Cell Lines.
Wang YL; Liui HL; Fu RG; Wang ZW; Ren HT; Dai ZJ; Jing YY; Li Y
Curr Mol Med; 2016; 16(3):232-42. PubMed ID: 26917266
[TBL] [Abstract][Full Text] [Related]
8. Proteomic analysis reveals a role for PAX8 in peritoneal colonization of high grade serous ovarian cancer that can be targeted with micelle encapsulated thiostrepton.
Hardy LR; Pergande MR; Esparza K; Heath KN; Önyüksel H; Cologna SM; Burdette JE
Oncogene; 2019 Aug; 38(32):6003-6016. PubMed ID: 31296958
[TBL] [Abstract][Full Text] [Related]
9. C-terminal binding protein-2 regulates response of epithelial ovarian cancer cells to histone deacetylase inhibitors.
Barroilhet L; Yang J; Hasselblatt K; Paranal RM; Ng SK; Rauh-Hain JA; Welch WR; Bradner JE; Berkowitz RS; Ng SW
Oncogene; 2013 Aug; 32(33):3896-903. PubMed ID: 22945647
[TBL] [Abstract][Full Text] [Related]
10. Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin.
Hayashi A; Horiuchi A; Kikuchi N; Hayashi T; Fuseya C; Suzuki A; Konishi I; Shiozawa T
Int J Cancer; 2010 Sep; 127(6):1332-46. PubMed ID: 20049841
[TBL] [Abstract][Full Text] [Related]
11. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
[TBL] [Abstract][Full Text] [Related]
12. Loss of PAX8 in high-grade serous ovarian cancer reduces cell survival despite unique modes of action in the fallopian tube and ovarian surface epithelium.
Rodgers LH; Ó hAinmhire E; Young AN; Burdette JE
Oncotarget; 2016 May; 7(22):32785-95. PubMed ID: 27129161
[TBL] [Abstract][Full Text] [Related]
13. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
14. Inhibition of DNA methyltransferases, histone deacetylases and lysine-specific demethylase-1 suppresses the tumorigenicity of the ovarian cancer ascites cell line SKOV3.
Meng F; Sun G; Zhong M; Yu Y; Brewer MA
Int J Oncol; 2013 Aug; 43(2):495-502. PubMed ID: 23709006
[TBL] [Abstract][Full Text] [Related]
15. HDAC is indispensable for IFN-γ-induced B7-H1 expression in gastric cancer.
Deng R; Zhang P; Liu W; Zeng X; Ma X; Shi L; Wang T; Yin Y; Chang W; Zhang P; Wang G; Tao K
Clin Epigenetics; 2018 Dec; 10(1):153. PubMed ID: 30537988
[TBL] [Abstract][Full Text] [Related]
16. Candidate genes and pathways downstream of PAX8 involved in ovarian high-grade serous carcinoma.
de Cristofaro T; Di Palma T; Soriano AA; Monticelli A; Affinito O; Cocozza S; Zannini M
Oncotarget; 2016 Jul; 7(27):41929-41947. PubMed ID: 27259239
[TBL] [Abstract][Full Text] [Related]
17. Histone Deacetylase Inhibitors as Anticancer Drugs.
Eckschlager T; Plch J; Stiborova M; Hrabeta J
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28671573
[TBL] [Abstract][Full Text] [Related]
18. Adipose-derived mesenchymal stem cells induced PAX8 promotes ovarian cancer cell growth by stabilizing TAZ protein.
Chu Y; Zhu C; Wang Q; Liu M; Wan W; Zhou J; Han R; Yang J; Luo W; Liu C; Zhou H; Li M; Yu F; Ye Y
J Cell Mol Med; 2021 May; 25(9):4434-4443. PubMed ID: 33830648
[TBL] [Abstract][Full Text] [Related]
19. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
Hanikoglu A; Hanikoglu F; Ozben T
Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
[TBL] [Abstract][Full Text] [Related]
20. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
Bandolik JJ; Hamacher A; Schrenk C; Weishaupt R; Kassack MU
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
